Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

View original at finance.yahoo.com
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech USA Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Anticipate CARVYKTI franchise FY 2025 profitability

    80% confidence

  • CARVYKTI cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy, with its continued record-breaking performance culminating in the achievement of more than 10,000 patients treated earlier this year

    80% confidence

  • Targeting multiple investigational new drug (IND) filings for oncology and autoimmune indications starting in second half 2026

    80% confidence

  • The Company believes cash and cash equivalents, and time deposits of approximately $1.0 billion as of September 30, 2025, will provide financial runway beyond 2026

    80% confidence

  • Triple-class-exposed patients treated with three prior lines of therapy from the CARTITUDE-1 and CARTITUDE-4 trials achieved a median progression-free survival of 50.4 months following a single infusion of CARVYKTI

    80% confidence

  • Legend Biotech is poised for transformative growth in 2026, as we work to achieve profitability this year by driving global adoption of CARVYKTI

    80% confidence

  • Expect company-wide operating profit in 2026

    80% confidence

  • The latest NCCN guidelines recommend talquetamab as a bridging therapy before CAR-T treatment for people with relapsed/refractory multiple myeloma to help keep patients eligible for CARVYKTI and improve outcomes

    80% confidence

  • Patients treated earlier, after one or two prior lines of therapy, exhibited greater immune fitness and a more immunocompetent tumor microenvironment, potential biological indicators of longer progression-free survival

    80% confidence

  • We're also committed to leveraging our proven CAR-T development platform to frontline multiple myeloma and promising new in vivo and allogeneic opportunities to extend our leadership in cell therapy innovation

    80% confidence

  • First-in-human data for in vivo dual CD20/CD19 therapy expected starting in the second half of 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference — Source | Via News | ViaNews EU